 |
Counteracting Bone Loss Associated With Breast Cancer Therapies CME Author Information and Disclosures Release Date: June 24, 2008; Valid for credit through June 24, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - List side-effect profiles of aromatase inhibitors (AIs) for women with hormone-sensitive breast cancer
- Determine optimal bone loss prevention strategies in patients undergoing AI therapy
- Discuss methods of monitoring therapy for bone health
Authors and Disclosures Paul E. Goss, MD, PhD
Disclosure: Paul E. Goss, MD, PhD, has disclosed that he has served as a speaker for Novartis, Pfizer, AstraZeneca, and GlaxoSmithKline. Joyce A. O'Shaughnessy, MD
Disclosure: Joyce A. O'Shaughnessy, MD, has disclosed that
she has served as an advisor or consultant to GNE, Pfizer, Novartis, AstraZeneca, Biogen, Genzyme, and MPI. Dr. O'Shaughnessy has also disclosed that she has served on the speaker's bureau for Lilly, sanofi-aventis, Abraxis, and AstraZeneca. Eleftherios P. Mamounas, MD
Disclosure: Eleftherios P. Mamounas, MD, has disclosed that he has received grants for educational activities from Aventis, Pfizer, Genentech,
and GHI. Dr. Mamounas has also disclosed that he has served as an advisor or consultant to Aventis, Pfizer, Genentech, GHI, Roche, Novartis, Lilly, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, and Abraxis. Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships. Ammar Hasan, PharmD
Disclosure: Ammar Hasan, PharmD, has
disclosed no relevant financial relationships. Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
